Long‐Term Drug Treatment of Obesity in a Private Practice Setting
Authors:
- Richard L. AtkinsonRARichard L. Atkinson
- Nikhil V. DhurandharNDNikhil V. Dhurandhar
- With Clinical And Technical Assistance Of Jon LevineWLWith Clinical And Technical Assistance Of Jon Levine
- Eric ChanECEric Chan
- 1 November 1997
- journal article
- Published by Wiley in Obesity Research
- Vol. 5 (6) , 578-586
Abstract
ATKINSON, RICHARD L, ROY C BLANK, DONALD SCHUMACHER, NIKHIL V DHURANDHAR, DOUGLAS L RITCH. Long‐term drug treatment of obesity in a private practice setting.This study evaluated the long‐term efficacy and safety of the combination of phentermine and fenfluramine for the treatment of obesity in a private practice setting. A total of 1388 consecutive, qualified patients presenting to a private general internal medicine practice in Charlotte, NC, were enrolled with eligibility criteria including: age 18 years to 60 years, 20% over “desirable” bodyweight or body mass index to drug therapy. Patients were instructed in diet, exercise, and behavior modification techniques and received phentermine (15 mg/day to 30 mg/day) and fenfluramine (20 mg/day to 60 mg/day) continuously for over 3 years. Average duration of treatment was 15. 9 months, and average weight loss at the last visit was 11. 6 kg, or 11. 7% of initial bodyweight. For patients completing 1 year of drug treatment, mean weight loss was 16. 5 kg, or 16% of initial weight. Weight loss persisted for 2 years, but partial regain was seen at 3 years. The dropout rates were 18% at 6 months, 39% at 1 year, 68% at 2 years, and 78% at 3 years. At 1 year, blood pressure of hypertensive patients fell from 151/95 mm Hg to 127/78 mm Hg, and serum cholesterol and triglycerides of hyperlipidemic patients fell by 0. 750 mmol/L (29 mg/dL) and 0. 937 mmol/L (83 mg/dL), respectively. Adverse events were modest. We conclude that, in a private practice setting, long‐term treatment of obesity with the combination of phentermine, fenfluramine, and a weight maintenance program is generally safe and effective. More research is needed to determine efficacy and safety for longer than 3 years.Keywords
This publication has 27 references indexed in Scilit:
- Pharmacotherapy for Obesity — Do the Benefits Outweigh the Risks?New England Journal of Medicine, 1996
- Appetite-Suppressant Drugs and the Risk of Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- A Double‐Blind Randomized Placebo‐Controlled Trial of SibutramineObesity Research, 1996
- Current Status of the Human Obesity Gene MapObesity Research, 1996
- Increasing Prevalence of Overweight Among US AdultsJAMA, 1994
- Primary pulmonary hypertension and fenfluramine use.Heart, 1993
- Genetics of ObesityAnnual Review of Nutrition, 1993
- Fluoxetine: A Randomized Clinical Trial in the Maintenance of Weight LossObesity Research, 1993
- INTERNATIONAL TRIAL OF LONG-TERM DEXFENFLURAMINE IN OBESITYThe Lancet, 1989
- Endocrine function in human obesityMetabolism, 1981